These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3716823)

  • 21. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of serum protein binding on hepatic clearance of S-disopyramide in the rabbit.
    Huang JD; Oie S
    J Pharm Pharmacol; 1985 Jul; 37(7):471-5. PubMed ID: 2863349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental evidence for concentration-dependent plasma protein binding effects on the apparent half-lives of restrictively cleared drugs.
    Lima JJ
    J Pharm Sci; 1983 Apr; 72(4):461-2. PubMed ID: 6864491
    [No Abstract]   [Full Text] [Related]  

  • 28. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
    Cook CS; Karim A; Sollman P
    Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
    Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
    Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disopyramide binding to serum protein in man and animals.
    Lima JJ; Haughey DB
    Drug Metab Dispos; 1981; 9(6):582-3. PubMed ID: 6120822
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
    Huang JD; Oie S
    J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human pharmacokinetics and metabolism of disopyramide enantiomers.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of surgery on the elimination kinetics of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HO; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Jul; 59(1):86-8. PubMed ID: 3766155
    [No Abstract]   [Full Text] [Related]  

  • 38. Direct enantiomeric resolution of disopyramide and its metabolite using chiral high-performance liquid chromatography. Application to stereoselective metabolism and pharmacokinetics of racemic disopyramide in man.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    J Chromatogr; 1988 Oct; 450(2):211-6. PubMed ID: 3235589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renal clearance of disopyramide after bolus intravenous injection.
    Lawrence JR; Bryson SM; Sumner DJ; Campbell BC; Whiting B
    Biopharm Drug Dispos; 1979; 1(2):51-7. PubMed ID: 552861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.